Sarepta Therapeutics, Inc. (SRPT) Balance Sheet
SRPT balance sheet, 2025
December 31, 2025 · U.S. dollars$3.35B assets = $2.21B liabilities + $1.14B equity
Both columns are drawn to the same scale: what SRPT owns equals what it owes plus shareholders’ equity. Hover a block for its value.
SRPT financial health
Descriptive bands, not a rating. Fiscal 2025.
SRPT balance sheet trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $424.1M2016 | $3.35B2025 | +25.8%/yr | |
| Total liabilities | $87.4M2016 | $2.21B2025 | +43.2%/yr | |
| Shareholders’ equity | $336.7M2016 | $1.14B2025 | +14.5%/yr | |
| Cash & short-term investments | $317.8M2016 | $939.6M2025 | +12.8%/yr | |
| Total debt | $16.1M2016 | $1.04B2025 | +58.8%/yr | |
| Net cash (debt) | $301.7M2016 | −$100.1M2025 | −$401.8M | |
| Working capital | $298.1M2016 | $1.44B2025 | +$1.1B | |
| Book value per share | $6.912016 | $10.882025 | +5.2%/yr | |
| Current ratio | 4.952016 | 2.322025 | −2.63 | |
| Debt / equity | 0.052016 | 0.912025 | +0.86 | |
| Shares outstanding | 48.7M2016 | 104.8M2025 | +8.9%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
SRPT assets
SRPT liabilities and equity
SRPT debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
SRPT balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $939.6M | $1.35B | $1.68B | $1.99B | $2.12B | $1.94B | $1.12B | $1.17B | $1.08B | $317.8M |
| Cash & equivalents | $801.3M | $1.10B | $428.4M | $966.8M | $2.12B | $1.50B | $835.1M | $370.8M | $599.7M | $122.4M |
| Short-term investments | $138.4M | $251.8M | $1.25B | $1.02B | $0 | $435.9M | $289.7M | $803.1M | $479.4M | $195.4M |
| Receivables | $519.6M | $649.7M | $437.0M | $261.6M | $171.6M | $138.6M | $93.9M | $49.0M | $29.5M | $5.2M |
| Inventory | $914.7M | $750.0M | $322.9M | $204.0M | $186.2M | $232.0M | $171.4M | $125.4M | $83.6M | $12.8M |
| Other current assets | $163.9M | $319.0M | $143.2M | $102.9M | $130.4M | $176.1M | $78.8M | $77.8M | $36.5M | $37.6M |
| Total current assets | $2.54B | $3.07B | $2.58B | $2.56B | $2.60B | $2.49B | $1.47B | $1.43B | $1.23B | $373.5M |
| Property, plant & equipment (net) | $470.6M | $488.6M | $357.1M | $245.0M | $236.7M | $282.2M | $167.6M | $97.0M | $43.2M | $37.8M |
| Goodwill & intangible assets | $28.9M | $26.9M | $29.6M | $7.6M | $14.2M | $13.6M | $12.5M | $11.6M | $14.4M | $8.1M |
| Long-term investments | $10.6M | $136.9M | $6.5M | $31.3M | $34.9M | $38.8M | $31.9M | $107.3M | $21.8M | $0 |
| Other non-current assets | $301.6M | $237.3M | $292.0M | $286.6M | $258.1M | $164.9M | $141.9M | $0 | $0 | $4.8M |
| Total assets | $3.35B | $3.96B | $3.26B | $3.13B | $3.15B | $2.98B | $1.82B | $1.64B | $1.31B | $424.1M |
| Liabilities | ||||||||||
| Accounts payable | $280.8M | $214.4M | $164.9M | $95.9M | $76.7M | $111.1M | $68.1M | $33.8M | $8.5M | $29.7M |
| Short-term debt | $11.4M | $13.5M | $123.3M | $15.5M | $271.7M | $193.6M | $7.8M | $134.1M | $6.2M | $10.1M |
| Deferred revenue | $443.4M | $130.3M | $50.4M | $89.2M | $89.2M | $89.2M | $3.3M | $3.3M | $3.3M | $3.3M |
| Total current liabilities | $1.10B | $731.7M | $653.7M | $619.6M | $452.7M | $416.0M | $264.8M | $173.7M | $88.3M | $75.4M |
| Long-term debt | $829.0M | $1.14B | $1.13B | $1.54B | $1.10B | $992.5M | $681.9M | $420.6M | $424.9M | $6.0M |
| Lease obligations | $210.8M | $205.9M | $158.8M | $57.6M | $41.5M | $80.4M | $47.7M | — | — | — |
| Other long-term liabilities | $284.8M | $566.6M | $619.1M | $579.5M | $670.4M | $814.4M | $58.0M | $15.6M | $5.5M | $5.9M |
| Total liabilities | $2.21B | $2.44B | $2.41B | $2.74B | $2.22B | $2.22B | $1.00B | $609.8M | $518.7M | $87.4M |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $11,000 | $10,000 | $9,000 | $9,000 | $9,000 | $8,000 | $8,000 | $7,000 | $6,000 | $1.50B |
| Retained earnings (deficit) | −$4.88B | −$4.21B | −$4.45B | −$3.91B | −$3.21B | −$2.85B | −$2.29B | −$1.58B | −$1.22B | −$1.17B |
| Treasury stock | — | — | — | — | — | — | — | — | $0 | $0 |
| Accumulated other comprehensive income | $272,000 | −$218,000 | $918,000 | −$1.7M | −$20,000 | $3,000 | $50,000 | −$99,000 | −$379,000 | −$120,000 |
| Minority interest | — | — | — | — | — | — | — | — | $0 | $0 |
| Total shareholders' equity | $1.14B | $1.53B | $859.3M | $384.9M | $928.0M | $761.8M | $818.2M | $1.03B | $789.2M | $336.7M |
| Key figures | ||||||||||
| Total debt | $1.04B | $1.34B | $1.40B | $1.62B | $1.37B | $1.19B | $737.5M | $554.6M | $431.1M | $16.1M |
| Net cash (debt) | −$100.1M | $11.7M | $279.4M | $372.0M | $747.3M | $752.5M | $387.3M | $619.3M | $648.0M | $301.7M |
| Working capital | $1.44B | $2.34B | $1.93B | $1.94B | $2.15B | $2.07B | $1.20B | $1.25B | $1.14B | $298.1M |
| Tangible book value | $1.11B | $1.50B | $829.7M | $377.4M | $913.8M | $748.1M | $805.7M | $1.02B | $774.9M | $328.6M |
| Book value per share | $10.88 | $14.16 | $9.30 | $4.40 | $11.42 | $9.77 | $11.11 | $15.58 | $13.42 | $6.91 |
| Shares outstanding | 104.8M | 107.9M | 92.4M | 87.6M | 81.3M | 78.0M | 73.6M | 66.2M | 58.8M | 48.7M |
| Current ratio | 2.32 | 4.20 | 3.95 | 4.13 | 5.75 | 5.97 | 5.55 | 8.21 | 13.91 | 4.95 |
| Quick ratio | 1.33 | 2.74 | 3.23 | 3.63 | 5.05 | 4.99 | 4.60 | 7.04 | 12.55 | 4.28 |
| Debt / equity | 0.91 | 0.88 | 1.63 | 4.20 | 1.47 | 1.56 | 0.90 | 0.54 | 0.55 | 0.05 |
| Equity / assets | 34.1% | 38.5% | 26.3% | 12.3% | 29.5% | 25.5% | 44.9% | 62.9% | 60.3% | 79.4% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $788.5M | $653.2M | $939.6M | $851.0M | $800.1M | $522.8M | $1.35B | $1.20B | $1.46B | $1.39B | $1.68B | $1.73B |
| Cash & equivalents | $571.1M | $464.4M | $801.3M | $613.1M | $510.6M | $240.9M | $1.10B | $197.9M | $383.6M | $427.3M | $428.4M | $541.9M |
| Short-term investments | $217.3M | $188.7M | $138.4M | $237.9M | $289.5M | $281.9M | $251.8M | $1.00B | $1.08B | $963.5M | $1.25B | $1.19B |
| Receivables | $482.6M | $547.9M | $519.6M | $541.6M | $609.6M | $724.5M | $649.7M | $516.0M | $392.3M | $419.4M | $437.0M | $354.3M |
| Inventory | $904.3M | $1.00B | $914.7M | $1.08B | $994.0M | $941.4M | $750.0M | $565.9M | $485.8M | $373.5M | $322.9M | $244.0M |
| Other current assets | $48.5M | $107.7M | $163.9M | $252.5M | $253.2M | $243.8M | $319.0M | $405.1M | $345.1M | $281.2M | $143.2M | $119.0M |
| Total current assets | $2.22B | $2.31B | $2.54B | $2.72B | $2.66B | $2.43B | $3.07B | $2.69B | $2.68B | $2.46B | $2.58B | $2.45B |
| Property, plant & equipment (net) | $446.8M | $460.3M | $470.6M | $498.1M | $514.9M | $507.6M | $488.6M | $446.7M | $400.2M | $375.6M | $357.1M | $345.8M |
| Goodwill & intangible assets | $30.6M | $31.4M | $28.9M | $29.7M | $30.5M | $26.2M | $26.9M | $27.6M | $28.3M | $28.9M | $29.6M | $19.5M |
| Long-term investments | $151.7M | $89.7M | $10.6M | $9.2M | $34.6M | $109.1M | $136.9M | $186.5M | $7.6M | $41.4M | $6.5M | $13.4M |
| Other non-current assets | $335.5M | $287.6M | $301.6M | $234.1M | $442.8M | $389.9M | $237.3M | $253.8M | $304.6M | $313.6M | $292.0M | $280.1M |
| Total assets | $3.19B | $3.18B | $3.35B | $3.49B | $3.68B | $3.47B | $3.96B | $3.60B | $3.42B | $3.22B | $3.26B | $3.11B |
| Liabilities | ||||||||||||
| Accounts payable | $51.0M | $70.4M | $280.8M | $94.0M | $136.7M | $156.1M | $214.4M | $118.8M | $107.4M | $91.5M | $164.9M | $87.9M |
| Short-term debt | — | — | $11.4M | $10.2M | — | — | $13.5M | $91.6M | $91.5M | $105.6M | $123.3M | $322.4M |
| Deferred revenue | $110.1M | $116.0M | $443.4M | $485.4M | $395.4M | $44.9M | $130.3M | $127.0M | $122.0M | $112.0M | $50.4M | $22.5M |
| Total current liabilities | $502.9M | $499.2M | $1.10B | $921.4M | $919.9M | $605.6M | $731.7M | $699.5M | $688.5M | $608.7M | $653.7M | $450.7M |
| Long-term debt | $847.6M | $838.2M | $829.0M | $1.04B | $1.14B | $1.14B | $1.14B | $1.14B | $1.13B | $1.13B | $1.13B | $1.24B |
| Lease obligations | $198.2M | $198.5M | $210.8M | $215.0M | $214.4M | $205.5M | $205.9M | $170.0M | $143.6M | $140.1M | $158.8M | $134.8M |
| Other long-term liabilities | $310.2M | $336.5M | $284.8M | $216.7M | $263.0M | $578.8M | $566.6M | $543.4M | $523.9M | $520.8M | $619.1M | $657.9M |
| Total liabilities | $1.66B | $1.67B | $2.21B | $2.17B | $2.32B | $2.32B | $2.44B | $2.38B | $2.35B | $2.26B | $2.41B | $2.35B |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $11,000 | $11,000 | $11,000 | $11,000 | $10,000 | $10,000 | $10,000 | $10,000 | $10,000 | $9,000 | $9,000 | $9,000 |
| Retained earnings (deficit) | −$4.55B | −$4.55B | −$4.88B | −$4.64B | −$4.46B | −$4.66B | −$4.21B | −$4.37B | −$4.40B | −$4.41B | −$4.45B | −$4.49B |
| Accumulated other comprehensive income | −$565,000 | −$121,000 | $272,000 | $220,000 | −$51,000 | $34,000 | −$218,000 | $2.2M | −$1.0M | −$691,000 | $918,000 | −$638,000 |
| Total shareholders' equity | $1.53B | $1.51B | $1.14B | $1.32B | $1.36B | $1.14B | $1.53B | $1.22B | $1.08B | $961.2M | $859.3M | $764.4M |
| Key figures | ||||||||||||
| Total debt | $1.05B | $1.04B | $1.04B | $1.25B | $1.35B | $1.34B | $1.34B | $1.40B | $1.37B | $1.38B | $1.40B | $1.37B |
| Net cash (debt) | −$257.4M | −$383.5M | −$100.1M | −$399.2M | −$553.7M | −$821.0M | $11.7M | −$199.2M | $90.6M | $11.4M | $279.4M | $362.0M |
| Working capital | $1.72B | $1.81B | $1.44B | $1.80B | $1.74B | $1.83B | $2.34B | $1.99B | $2.00B | $1.86B | $1.93B | $2.00B |
| Tangible book value | $1.50B | $1.47B | $1.11B | $1.29B | $1.33B | $1.12B | $1.50B | $1.19B | $1.05B | $932.3M | $829.7M | $744.9M |
| Book value per share | $14.49 | $12.35 | $10.88 | $13.17 | $12.73 | $11.74 | $14.08 | $12.16 | $10.86 | $9.70 | $8.14 | $8.60 |
| Shares outstanding | 105.4M | 121.9M | 104.8M | 100.2M | 106.6M | 97.4M | 108.5M | 100.4M | 99.1M | 99.1M | 105.6M | 88.9M |
| Current ratio | 4.42 | 4.63 | 2.32 | 2.95 | 2.89 | 4.02 | 4.20 | 3.84 | 3.90 | 4.05 | 3.95 | 5.44 |
| Quick ratio | 2.53 | 2.41 | 1.33 | 1.51 | 1.53 | 2.06 | 2.74 | 2.45 | 2.69 | 2.97 | 3.23 | 4.63 |
| Debt / equity | 0.68 | 0.69 | 0.91 | 0.95 | 1.00 | 1.18 | 0.88 | 1.14 | 1.27 | 1.44 | 1.63 | 1.79 |
| Equity / assets | 47.9% | 47.3% | 34.1% | 37.8% | 36.9% | 33.0% | 38.5% | 33.9% | 31.5% | 29.8% | 26.3% | 24.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 2, 2026); data from EODHD.
SRPT financial position
At the end of fiscal 2025 (December 31, 2025), Sarepta Therapeutics had total assets of $3.3 billion (down 15.5% from a year earlier), total liabilities of $2.2 billion and shareholders' equity of $1.1 billion. It held $939.6 million in cash and short-term investments against $1.0 billion of debt, net debt of $100.1 million. Its current ratio was 2.32. In the latest quarter (ended June 30, 2026) total assets were $3.2 billion and equity $1.5 billion.
Related: SRPT income statement, SRPT cash flow statement, SRPT key metrics. See the SRPT stock overview for the latest quote and news.
SRPT balance sheet FAQ
What are Sarepta Therapeutics's total assets?
Sarepta Therapeutics reported total assets of $3.3 billion at the end of fiscal 2025 (December 31, 2025), compared with $4.0 billion a year earlier.
How much debt does Sarepta Therapeutics have?
Sarepta Therapeutics had $1.0 billion of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.91.
How much cash does Sarepta Therapeutics have?
Sarepta Therapeutics held $939.6 million in cash and short-term investments at the end of fiscal 2025; with $1.0 billion of debt that is net debt of $100.1 million.
What is Sarepta Therapeutics's book value?
Sarepta Therapeutics's shareholders' equity (book value) was $1.1 billion at the end of fiscal 2025, or $10.88 per share.
What is Sarepta Therapeutics's current ratio?
Sarepta Therapeutics had current assets of $2.5 billion and current liabilities of $1.1 billion, a current ratio of 2.32 (it can cover its short-term obligations).
How much goodwill does Sarepta Therapeutics have?
Sarepta Therapeutics carried $28.9 million of goodwill and intangible assets, 0.9% of total assets, at the end of fiscal 2025.